(Q53960639)

23 May 2018

title

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. (English)

1 reference

23 May 2018

1 reference

P G Watson

1

1 reference

23 May 2018

publication date

1 January 1998

1 reference

23 May 2018

published in

Ophthalmology

1 reference

23 May 2018

volume

105

1 reference

23 May 2018

issue

1

1 reference

23 May 2018

page(s)

82-87

1 reference

23 May 2018

PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

Melanocytes and iris color. Electron microscopic findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

Melanocytes and iris color. Light microscopic findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2898%2991372-0

7 January 2021

10.1016/S0161-6420(98)91372-0

Identifiers

DOI

1 reference

23 May 2018

PubMed ID

9442782

1 reference

23 May 2018